[go: up one dir, main page]

BR9509669A - Compostos azetidinona substituídos com enxofre úteis como agents hipocolesterolêmicos - Google Patents

Compostos azetidinona substituídos com enxofre úteis como agents hipocolesterolêmicos

Info

Publication number
BR9509669A
BR9509669A BR9509669A BR9509669A BR9509669A BR 9509669 A BR9509669 A BR 9509669A BR 9509669 A BR9509669 A BR 9509669A BR 9509669 A BR9509669 A BR 9509669A BR 9509669 A BR9509669 A BR 9509669A
Authority
BR
Brazil
Prior art keywords
aryl
coor6
lower alkyl
nr6r7
substituted
Prior art date
Application number
BR9509669A
Other languages
English (en)
Inventor
Brian A Mckittrick
Sundeep Dugar
Duane A Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/342,197 external-priority patent/US5624920A/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of BR9509669A publication Critical patent/BR9509669A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Pyridine Compounds (AREA)
BR9509669A 1994-11-18 1995-11-15 Compostos azetidinona substituídos com enxofre úteis como agents hipocolesterolêmicos BR9509669A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/342,197 US5624920A (en) 1994-11-18 1994-11-18 Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
US08/463,619 US5633246A (en) 1994-11-18 1995-06-05 Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents
PCT/US1995/014134 WO1996016037A1 (en) 1994-11-18 1995-11-15 Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents

Publications (1)

Publication Number Publication Date
BR9509669A true BR9509669A (pt) 1997-10-28

Family

ID=26992866

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9509669A BR9509669A (pt) 1994-11-18 1995-11-15 Compostos azetidinona substituídos com enxofre úteis como agents hipocolesterolêmicos

Country Status (24)

Country Link
US (2) US5633246A (pt)
EP (1) EP0792264B1 (pt)
JP (1) JP2908031B2 (pt)
KR (1) KR100235806B1 (pt)
CN (1) CN1083833C (pt)
AT (1) ATE213726T1 (pt)
AU (1) AU698750B2 (pt)
BR (1) BR9509669A (pt)
CA (1) CA2205202C (pt)
CZ (1) CZ289033B6 (pt)
DE (1) DE69525643T2 (pt)
DK (1) DK0792264T3 (pt)
ES (1) ES2169162T3 (pt)
FI (1) FI116220B (pt)
HU (1) HU227672B1 (pt)
MX (1) MX9703577A (pt)
NO (1) NO308468B1 (pt)
NZ (1) NZ296720A (pt)
PL (1) PL184310B1 (pt)
PT (1) PT792264E (pt)
RU (1) RU2159243C2 (pt)
SK (1) SK283860B6 (pt)
UA (1) UA54381C2 (pt)
WO (1) WO1996016037A1 (pt)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5631365A (en) 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
MY114803A (en) 1995-10-31 2003-01-31 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
US5756470A (en) * 1996-10-29 1998-05-26 Schering Corporation Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents
JP2002518478A (ja) * 1998-06-25 2002-06-25 ブリストル−マイヤーズ スクイブ カンパニー アミジノおよびグアニジノアゼチジノントリプターゼ阻害剤
US6297268B1 (en) 1999-11-30 2001-10-02 Schering Corporation Imidazoles as cholesterol lowering agents
US6584357B1 (en) * 2000-10-17 2003-06-24 Sony Corporation Method and system for forming an acoustic signal from neural timing difference data
CZ302193B6 (cs) * 2000-12-20 2010-12-08 Schering Corporation 2-azetidinonové deriváty, substituované zbytkem cukru
US6982251B2 (en) 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
EP1510521A1 (en) * 2000-12-20 2005-03-02 Schering Corporation Sugar-substituted 2-Azetidinones useful as hypocholesterolemic agents
US7071181B2 (en) 2001-01-26 2006-07-04 Schering Corporation Methods and therapeutic combinations for the treatment of diabetes using sterol absorption inhibitors
RS50406B (sr) * 2001-01-26 2009-12-31 Schering Corporation, Upotreba supstituisanih jedinjenja azetidinona za lečenje sitosterolemije
SI1413331T1 (sl) 2001-01-26 2008-02-29 Schering Corp Kombinacije fenofibrata peroksisomskega proliferator aktivirajocega receptorja (PPAR) z ezetimib zaviralcem absorpcije sterola za vaskularne indikacije
EP1911462A3 (en) 2001-01-26 2011-11-30 Schering Corporation Compositions comprising a sterol absorption inhibitor
US20060287254A1 (en) * 2001-01-26 2006-12-21 Schering Corporation Use of substituted azetidinone compounds for the treatment of sitosterolemia
UA75644C2 (en) 2001-03-28 2006-05-15 Schering Corp Enantioselective synthesis of azetidinone intermediate compounds
US7053080B2 (en) 2001-09-21 2006-05-30 Schering Corporation Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
MXPA04002573A (es) * 2001-09-21 2004-06-18 Schering Corp Tratamiento de xantoma con derivados de azetidinona como inhibidores de la absorcion de esterol.
EP1859796A3 (en) * 2001-09-21 2008-07-02 Schering Corporation Treatment of xanthoma with azetidinone derivatives as sterol absorption inhibitors
US7056906B2 (en) * 2001-09-21 2006-06-06 Schering Corporation Combinations of hormone replacement therapy composition(s) and sterol absorption inhibitor(s) and treatments for vascular conditions in post-menopausal women
US20030204096A1 (en) * 2002-03-25 2003-10-30 Schering Corporation Enantioselective synthesis of azetidinone intermediate compounds
GB0215579D0 (en) * 2002-07-05 2002-08-14 Astrazeneca Ab Chemical compounds
US7135556B2 (en) * 2002-07-19 2006-11-14 Schering Corporation NPC1L1 (NPC3) and methods of use thereof
AR040588A1 (es) 2002-07-26 2005-04-13 Schering Corp Formulacion farmaceutica que comprende un inhibidor de la absorcion del colesterol y un inhibidor de una hmg- co a reductasa
EP1562582A1 (en) 2002-11-06 2005-08-17 Schering Corporation Cholesterol absorption inhibitors for the treatment of demyelination
JP4589919B2 (ja) 2003-03-07 2010-12-01 シェーリング コーポレイション 高コレステロール血症の処置のための、置換アゼチジノン化合物、これらの処方物および使用
US7459442B2 (en) 2003-03-07 2008-12-02 Schering Corporation Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
US7192944B2 (en) 2003-03-07 2007-03-20 Schering Corp. Substituted azetidinone compounds, processes for preparing the same, formulations and uses thereof
ES2311806T3 (es) 2003-03-07 2009-02-16 Schering Corporation Compuesto de azetidinona sustituidos, fornulaciones y usos de los mismos para el tratamiento de hipercolesterolemia.
DE10314610A1 (de) * 2003-04-01 2004-11-04 Aventis Pharma Deutschland Gmbh Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
US20050113314A1 (en) * 2003-08-29 2005-05-26 Fong Benson M. Cicletanine in combination with oral antidiabetic and/or blood lipid-lowering agents as a combination therapy for diabetes and metabolic syndrome
EP1522541A1 (en) * 2003-10-07 2005-04-13 Lipideon Biotechnology AG Novel hypocholesterolemic compounds
EP1918000A2 (en) 2003-11-05 2008-05-07 Schering Corporation Combinations of lipid modulating agents and substituted azetidinones and treatments for vascular conditions
RU2380360C2 (ru) * 2003-12-23 2010-01-27 Астразенека Аб Дифенилазетидиноновые производные, обладающие активностью, ингибирующей всасывание холестерина
JP2007516287A (ja) * 2003-12-23 2007-06-21 メルク　エンド　カムパニー　インコーポレーテッド 抗高コレステロール血症化合物
GB0329778D0 (en) * 2003-12-23 2004-01-28 Astrazeneca Ab Chemical compounds
ATE485267T1 (de) * 2003-12-23 2010-11-15 Astrazeneca Ab Diphenylazetidinonderivate mit die cholesterinabsorption hemmender wirkung
WO2005069900A2 (en) * 2004-01-16 2005-08-04 Merck & Co., Inc. Npc1l1 (npc3) and methods of identifying ligands thereof
MX2007003732A (es) * 2004-09-29 2007-04-23 Schering Corp Combinaciones de azetidononas sustituidas y antagonistas de receptor de canabinoide 1.
SG163577A1 (en) 2004-12-03 2010-08-30 Schering Corp Substituted piperazines as cb1 antagonists
UY29607A1 (es) * 2005-06-20 2007-01-31 Astrazeneca Ab Compuestos quimicos
WO2007001975A1 (en) * 2005-06-20 2007-01-04 Schering Corporation Piperidine derivatives useful as histamine h3 antagonists
AR057380A1 (es) * 2005-06-22 2007-11-28 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona y uso terapeutico de los mismos
SA06270191B1 (ar) * 2005-06-22 2010-03-29 استرازينيكا ايه بي مشتقات من 2- أزيتيدينون جديدة باعتبارها مثبطات لامتصاص الكوليسترول لعلاج حالات فرط نسبة الدهون في الدم
AR057383A1 (es) * 2005-06-22 2007-12-05 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, formulacion farmaceutica y un proceso de preparacion del compuesto
AR056866A1 (es) * 2005-06-22 2007-10-31 Astrazeneca Ab Compuestos quimicos derivados de 2-azetidinona, una formulacion farmaceutica y un proceso de preparacion del compuesto
MY148538A (en) * 2005-06-22 2013-04-30 Astrazeneca Ab Novel 2-azetidinone derivatives as cholesterol absorption inhibitors for the treatment of hyperlipidaemic conditions
AR054482A1 (es) * 2005-06-22 2007-06-27 Astrazeneca Ab Derivados de azetidinona para el tratamiento de hiperlipidemias
AU2006331770A1 (en) * 2005-12-21 2007-07-05 Schering Corporation Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and H3 receptor antagonist/inverse agonist
US7897601B2 (en) 2006-01-18 2011-03-01 Intervet, Inc. Cannabinoid receptor modulators
US7910698B2 (en) 2006-02-24 2011-03-22 Schering Corporation NPC1L1 orthologues
RU2008136765A (ru) * 2006-03-06 2010-04-20 Тева Фармасьютикл Индастриес Лтд. (Il) Композиции эзетимиба
AR060623A1 (es) 2006-04-27 2008-07-02 Astrazeneca Ab Compuestos derivados de 2-azetidinona y un metodo de preparacion
JP2010502702A (ja) * 2006-09-05 2010-01-28 シェーリング コーポレイション 脂質管理およびアテローム性動脈硬化症および脂肪肝の治療治療において使用される医薬組成物
CN101528227A (zh) * 2006-09-15 2009-09-09 先灵公司 氮杂环丁酮衍生物及其使用方法
JP2010503672A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション 脂質代謝障害、疼痛、糖尿病、および他の障害を治療するためのスピロ環アゼチジノン誘導体
KR20090071589A (ko) 2006-09-15 2009-07-01 쉐링 코포레이션 통증 및 지질 대사 장애의 치료에 유용한 아제티딘 및 아제티돈 유도체
JP2010503675A (ja) * 2006-09-15 2010-02-04 シェーリング コーポレイション 疼痛、糖尿病および脂質代謝の障害の治療に有用なスピロ縮合アゼチジン誘導体
CA2663502A1 (en) * 2006-09-15 2008-03-20 Schering Corporation Azetidinone derivatives and methods of use thereof
AU2008221833A1 (en) 2007-03-06 2008-09-12 Teijin Pharma Limited 1-biarylazetidinone derivatives
US20100197564A1 (en) * 2007-04-19 2010-08-05 Schering Corporation Diaryl morpholines as cb1 modulators
WO2009005646A2 (en) * 2007-06-28 2009-01-08 Schering Corporation Substituted piperazines as cb1 antagonists
JP2010531874A (ja) * 2007-06-28 2010-09-30 インターベット インターナショナル ベー． フェー． Ｃｂ１アンタゴニストとしての置換ピペラジン
WO2010100255A1 (en) 2009-03-06 2010-09-10 Lipideon Biotechnology Ag Pharmaceutical hypocholesterolemic compositions
CN101993403B (zh) 2009-08-11 2012-07-11 浙江海正药业股份有限公司 氮杂环丁酮类化合物及医药应用
WO2013166117A1 (en) 2012-05-01 2013-11-07 Althera Life Sciences, Llc Oral tablet formulation consisting of fixed combination of rosuvastatin and ezetimibe for treatment of hyperlipidemia and cardiovascular diseases
WO2020191163A1 (en) 2019-03-20 2020-09-24 Regeneron Pharmaceuticals, Inc. Treatment of increased lipid levels with sterol regulatory element binding protein cleavage-activating protein (scap) inhibitors
JP7574206B2 (ja) 2019-03-20 2024-10-28 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ステロール調節エレメント結合転写因子１（ｓｒｅｂｆ１）阻害剤による上昇した脂質レベルの治療
WO2025049558A1 (en) 2023-08-29 2025-03-06 Regeneron Pharmaceuticals, Inc. Treatment of liver disease or metabolic disorder with folliculin interacting protein 1 (fnip1) inhibitors and/or folliculin (flcn) inhibitors

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680391A (en) * 1983-12-01 1987-07-14 Merck & Co., Inc. Substituted azetidinones as anti-inflammatory and antidegenerative agents
US4803266A (en) * 1986-10-17 1989-02-07 Taisho Pharmaceutical Co., Ltd. 3-Oxoalkylidene-2-azetidinone derivatives
GB8719695D0 (en) * 1987-08-20 1987-09-30 Ici Plc Chemical process
IL89835A0 (en) * 1988-04-11 1989-12-15 Merck & Co Inc Substituted azetidinones,their preparation and pharmaceutical compositions containing them
US4983597A (en) * 1989-08-31 1991-01-08 Merck & Co., Inc. Beta-lactams as anticholesterolemic agents
US5120729A (en) * 1990-06-20 1992-06-09 Merck & Co., Inc. Beta-lactams as antihypercholesterolemics
EP0596015B1 (en) * 1991-07-23 1997-10-01 Schering Corporation Substituted beta-lactam compounds useful as hypocholesterolemic agents and processes for the preparation thereof
LT3300B (en) * 1992-12-23 1995-06-26 Schering Corp Combination of a cholesterol biosynhtesis inhibitor and a beta- lactam cholesterol absorbtion inhibitor
US5412092A (en) * 1993-04-23 1995-05-02 Bristol-Myers Squibb Company N-substituted 2-azetidinones
US5631365A (en) * 1993-09-21 1997-05-20 Schering Corporation Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
US5627176A (en) * 1994-03-25 1997-05-06 Schering Corporation Substituted azetidinone compounds useful as hypocholesterolemic agents
JPH10501811A (ja) * 1994-06-20 1998-02-17 シェーリング コーポレイション 低コレステロール化剤として有用な置換アゼチジノン化合物
US5656624A (en) * 1994-12-21 1997-08-12 Schering Corporation 4-[(heterocycloalkyl or heteroaromatic)-substituted phenyl]-2-azetidinones useful as hypolipidemic agents
MY114803A (en) * 1995-10-31 2003-01-31 Schering Corp Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents

Also Published As

Publication number Publication date
JP2908031B2 (ja) 1999-06-21
HK1002558A1 (en) 1998-09-04
WO1996016037A1 (en) 1996-05-30
ATE213726T1 (de) 2002-03-15
NO972272D0 (no) 1997-05-16
US5633246A (en) 1997-05-27
NO308468B1 (no) 2000-09-18
CZ148697A3 (en) 1997-11-12
DE69525643T2 (de) 2002-09-26
CA2205202C (en) 2002-01-08
FI972099A7 (fi) 1997-05-16
RU2159243C2 (ru) 2000-11-20
AU698750B2 (en) 1998-11-05
PT792264E (pt) 2002-07-31
EP0792264A1 (en) 1997-09-03
DK0792264T3 (da) 2002-04-22
FI116220B (fi) 2005-10-14
HUT77088A (hu) 1998-03-02
CN1083833C (zh) 2002-05-01
SK61697A3 (en) 1997-12-10
PL184310B1 (pl) 2002-09-30
MX9703577A (es) 1997-08-30
KR970707092A (ko) 1997-12-01
JPH09512833A (ja) 1997-12-22
UA54381C2 (uk) 2003-03-17
DE69525643D1 (de) 2002-04-04
CA2205202A1 (en) 1996-05-30
FI972099A0 (fi) 1997-05-16
PL320092A1 (en) 1997-09-15
CN1174548A (zh) 1998-02-25
NO972272L (no) 1997-05-16
HU227672B1 (en) 2011-11-28
EP0792264B1 (en) 2002-02-27
CZ289033B6 (cs) 2001-10-17
SK283860B6 (sk) 2004-03-02
AU4140196A (en) 1996-06-17
NZ296720A (en) 1999-03-29
US5744467A (en) 1998-04-28
KR100235806B1 (ko) 2000-02-01
ES2169162T3 (es) 2002-07-01

Similar Documents

Publication Publication Date Title
BR9509669A (pt) Compostos azetidinona substituídos com enxofre úteis como agents hipocolesterolêmicos
TW427974B (en) Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents
ATE183738T1 (de) Substituierte azetidinon-verbindungen als hypocholesterolemische mittel
MX9606319A (es) Compuestos de acetidinonas sustituidas utiles como agentes hipocolesterolemicos.
IL133623A0 (en) Antithrombotic agents
IL133627A0 (en) Antithrombotic agents
BRPI9909282A (pt) compostos de éter aminociclohexílicos e usos dos mesmos.
ES2266459T3 (es) Uso de compuestos de azetidinona sustituidos para el tratamiento de sitosterolemia.
AR035739A1 (es) Composiciones farmaceuticas y combinaciones terapeuticas que comprenden secuestrante (s) de los acidos biliares y de inhibidor (es) de la absorcion de los esteroles y el uso de dichas composiciones para la manufactura de un medicamento para el tratamiento de indicaciones vasculares
EE04777B1 (et) Kasvajavastased ühendid, neid sisaldavad farmatseutilised kompositsioonid ning nende kasutamine
ATE229032T1 (de) 20-aralkyl-5,alpha,-pregnan derivate
AP2001002188A0 (en) 5HT1 antagonists for antidepressant therapy.
ATE247955T1 (de) Selenophen-antitumormittel
CA2261271A1 (en) Dihydrodibenzo[b,e]oxazepine derivatives and pharmaceutical composition containing the same
PT944618E (pt) Novos compostos de n-benzenossulfonilo-1-prolina processo de preparacao e utilizacao em terapia
EA200001157A2 (ru) Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции
ATE229804T1 (de) Antibakterielle carbapeneme, zusammensetzungen und verfahren zur behandlung

Legal Events

Date Code Title Description
FB36 Technical and formal requirements: requirement - article 36 of industrial property law
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]
B24H Lapse because of non-payment of annual fees (definitively: art 78 iv lpi)
B24F Patent annual fee: publication cancelled

Free format text: ANULADA A PUBLICACAO CODIGO 24.8 NA RPI NO 2259 DE 22/04/2014 POR TER SIDO INDEVIDA.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE AS 17A, 18A, 19A E 20A ANUIDADES.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2606 DE 15-12-2020 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.